Thymosin α1 Improves Survival in Severe Hepatitis B Liver Failure, RCT Finds

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Thymosin α1 is approved for clinical use in some countries but not currently FDA-approved in the United States for the indication discussed here. Do not start, stop, or change any treatment without consulting a licensed healthcare provider.

For decades, thymosin α1 has been used as an immune-modulating agent in countries across Asia and Europe — but its precise mechanism of action in severe liver disease has remained unclear. A new randomized controlled trial published in Immunopharmacology and Immunotoxicology in April 2026 brings new clarity, documenting how the peptide rebalances the immune system in one of the most dangerous forms of liver failure.

What Is Thymosin α1?

Thymosin α1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland, a central organ of the immune system. Its primary role is immune regulation — it influences T-cell maturation and function and helps calibrate the body’s inflammatory responses.

Synthetic thymosin α1 (marketed as Zadaxin in some markets) has been studied and used clinically for applications ranging from viral hepatitis to sepsis to certain cancers, particularly in Asian and European clinical settings. In the United States, it has investigational status but is not FDA-approved for any indication.

Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a particularly severe condition. Patients have underlying chronic liver disease, then experience an acute deterioration that drives the liver to the edge of failure. Mortality rates are high, and liver transplantation is the definitive treatment — but most patients either cannot access a transplant in time or do not meet criteria.

The trial (NCT03082885), conducted at the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou, China, enrolled 73 patients with HBV-ACLF. Patients were randomized to:

Standard medical therapy (SMT) — the current best available care (n = 38)
SMT plus thymosin α1 — standard care with regular Tα1 injections (n = 35)

The primary outcome was 90-day transplant-free survival.

Key Findings

Improved Survival

Patients who received thymosin α1 showed significantly improved 90-day transplant-free survival compared to the standard care group. For patients with this condition — where outcomes without transplant are often poor — this is a clinically meaningful result.

The Immune Mechanism

The study went beyond survival statistics to investigate why thymosin α1 helped. Researchers analyzed immune cell populations and cytokine levels in the blood throughout the treatment period.

Two patterns distinguished survivors from non-survivors at baseline:

Survivors had more effector T cells (TE) and fewer regulatory T cells (Tregs) — suggesting a more active, balanced immune state at the outset
Survivors had higher early pro-inflammatory markers (IL-6, TNF-α, IFN-γ) and lower levels of TGF-β — indicating a system that was fighting back appropriately

Over time, survivors showed a gradual, controlled decline in inflammatory markers. Non-survivors, by contrast, developed a progressive inflammatory storm — a runaway immune response that is itself lethal.

What Thymosin α1 Did

Thymosin α1 treatment was associated with:

Reduction in Tregs — particularly a subpopulation known as CD226^low/- Tregs — at weeks 4 through 8
Moderation of late-stage hyperinflammation — without suppressing the early immune activation that appears beneficial

This is a nuanced finding. In HBV-ACLF, the immune system’s failure mode is paradoxical: it can simultaneously be too suppressed (unable to control infection) and too activated (triggering damaging inflammation). Thymosin α1 appears to thread this needle — preventing immune paralysis while also preventing the runaway inflammation that causes organ failure.

As the authors describe it: Tα1 “breaks the cycle of hyperinflammation and immunosuppression” by recalibrating T-cell populations and cytokine production.

Why This Matters

Thymosin α1 is not a new molecule — it has been studied for decades — but this trial adds to a growing mechanistic understanding of how it works in acute severe disease. The randomized design (rather than observational data) strengthens confidence in the survival benefit finding.

For a condition like HBV-ACLF, where transplant access is limited and mortality is high, effective non-transplant interventions are critically needed. Thymosin α1 represents a biologically plausible candidate: it modulates, rather than bluntly suppresses, immune function.

The broader lesson from this trial is also relevant to ongoing peptide research: the immune system is not simply “high” or “low” — it operates in complex, context-specific states. Peptides that can fine-tune these states, rather than simply amplifying or suppressing them, may have particular value in conditions where immune balance is the core problem.

Limitations and Context

This is a single-center trial with 73 patients — a meaningful but modest sample size. Larger multi-center trials would strengthen the findings. The study was conducted in China, and the patient population (HBV-ACLF driven by chronic hepatitis B) may not map directly to liver failure patterns from other causes (e.g., alcohol-related liver disease, autoimmune hepatitis).

Thymosin α1 is also not available through standard channels in the United States — accessing it typically requires either clinical trial participation or medical travel. Readers should not attempt to source it through unregulated online vendors, which carry significant quality and safety risks.

Source

Li ZH, Wu LL, Zhu YQ, Hu ZX, Meng SB, Lei ZY, Cao HJ, Wang JL, Chen JF, Zhang J, Lin BL. “Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance.” Immunopharmacology and Immunotoxicology. April 2026;48(2):341–353. PMID: 41887933 | DOI: 10.1080/08923973.2026.2641686